{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:18:54Z","timestamp":1791875934133,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2873"],"award-info":[{"award-number":["GRK2873"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["494832089"],"award-info":[{"award-number":["494832089"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejmech.2026.118806","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T20:21:22Z","timestamp":1774815682000},"page":"118806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Fine-tuning the combination of novel spirocyclic capping moieties and heterocyclic zinc binding groups for selective HDAC6 inhibition: design, synthesis, kinetic and biological studies"],"prefix":"10.1016","volume":"311","author":[{"given":"Simona","family":"Barone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gessica","family":"Filocamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cerchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guadagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Hanl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Sch\u00e4ker-H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-3773","authenticated-orcid":false,"given":"Margherita","family":"Brindisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejmech.2026.118806_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118806_bib2","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118806_bib3","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1039\/C6CS00599C","article-title":"Epigenetic modification of nucleic acids: from basic studies to medical applications","volume":"46","author":"Chen","year":"2017","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","article-title":"The sirtuin family in health and disease","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cr.2018.11.001","article-title":"Nuclear-cytoplasmic shuttling of class IIa histone deacetylases regulates somatic cell reprogramming","volume":"8","author":"Luo","year":"2019","journal-title":"Cell Regen."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jnc.12058","article-title":"scp>SMRT<\/Scp> \u2010mediated Co\u2010shuttling enables export of class <scp>II<\/Scp> a <scp>HDAC<\/Scp> s independent of their CaM kinase phosphorylation sites","volume":"124","author":"Soriano","year":"2013","journal-title":"J. Neurochem."},{"issue":"44","key":"10.1016\/j.ejmech.2026.118806_bib7","doi-asserted-by":"crossref","first-page":"17335","DOI":"10.1073\/pnas.0706487104","article-title":"Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases","volume":"104","author":"Lahm","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118806_bib8","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3390\/cells11101626","article-title":"Targeting histone deacetylases in idiopathic pulmonary fibrosis: a future therapeutic option","volume":"11","author":"Korfei","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.118806_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116884","article-title":"Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isoform","volume":"279","author":"Guadagni","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118806_bib10","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1021\/acs.jmedchem.1c02067","article-title":"Chasing a breath of fresh air in cystic fibrosis (CF): therapeutic potential of selective HDAC6 inhibitors to tackle multiple pathways in CF pathophysiology","volume":"65","author":"Barone","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/acs.jmedchem.9b00924","article-title":"Old but gold: tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases","volume":"63","author":"Brindisi","year":"2020","journal-title":"J. Med. Chem."},{"issue":"31","key":"10.1016\/j.ejmech.2026.118806_bib12","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118806_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nchembio.1223","article-title":"Selective class IIa histone deacetylase inhibition via a nonchelating zinc-Binding group","volume":"9","author":"Lobera","year":"2013","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118806_bib14","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/acsmedchemlett.0c00532","article-title":"Evaluation of 5-(Trifluoromethyl)-1,2,4-Oxadiazole-Based class IIa HDAC inhibitors for Huntington's disease","volume":"12","author":"Stott","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118806_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115907","article-title":"5-(Trifluoromethyl)-1,2,4-Oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with Bortezomib","volume":"263","author":"Asfaha","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118806_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115730","article-title":"Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer","volume":"260","author":"Moi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2026.118806_bib17","doi-asserted-by":"crossref","first-page":"13821","DOI":"10.1021\/acs.jmedchem.3c01345","article-title":"Difluoromethyl-1,3,4-Oxadiazoles are selective, mechanism-based, and essentially irreversible inhibitors of histone deacetylase 6","volume":"66","author":"K\u00f6nig","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118806_bib18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1021\/acsptsci.4c00031","article-title":"2-(Difluoromethyl)-1,3,4-Oxadiazoles: the future of selective histone deacetylase 6 modulation?","volume":"7","author":"K\u00f6nig","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102800","article-title":"Difluoromethyl-1,3,4-Oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity","volume":"299","author":"Cellupica","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118806_bib20","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.3390\/ijms25115885","article-title":"Mechanistic and structural insights on Difluoromethyl-1,3,4-Oxadiazole inhibitors of HDAC6","volume":"25","author":"Cellupica","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118806_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117634","article-title":"Challenging triple negative breast cancer through HDAC6 selective inhibition: novel cap-group identification, structure-activity relationships, computational and biological studies","volume":"292","author":"Barone","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118806_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108055","article-title":"Selective HDAC6 inhibition by mesinostat impairs tumor growth and stemness in triple-negative breast cancer","volume":"222","author":"Bello","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118806_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116686","article-title":"Discovery of novel 2,8-Diazaspiro[4.5]Decan-1-One derivatives as potent RIPK1 kinase inhibitors","volume":"59","author":"Niu","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118806_bib24","unstructured":"WO_0206234_A1-2."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118806_bib25","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.drudis.2020.07.017","article-title":"Fsp3: a new parameter for drug-likeness","volume":"25","author":"Wei","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118806_bib26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118806_bib27","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118806_bib28","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1021\/acs.biochem.2c00332","article-title":"Aromatic ring fluorination patterns modulate inhibitory potency of fluorophenylhydroxamates complexed with histone deacetylase 6","volume":"61","author":"Watson","year":"2022","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118806_bib29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/biology12081049","article-title":"The importance of the \u201cTime Factor\u201d for the evaluation of inhibition mechanisms: the case of selected HDAC6 inhibitors","volume":"12","author":"Cellupica","year":"2023","journal-title":"Biology"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118806_bib30","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1021\/acsptsci.5c00247","article-title":"Target engagement studies and kinetic live-cell degradation assays enable the systematic characterization of histone deacetylase 6 degraders","volume":"8","author":"Hanl","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118806_bib31","article-title":"Balancing histone deacetylase (HDAC) inhibition and drug\u2010likeness: biological and physicochemical evaluation of class I selective HDAC inhibitors","volume":"17","author":"Sch\u00e4ker\u2010H\u00fcbner","year":"2022","journal-title":"ChemMedChem"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118806_bib32","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1021\/jacsau.4c00828","article-title":"Slow-binding and covalent HDAC inhibition: a new paradigm?","volume":"4","author":"Raouf","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.ejmech.2026.118806_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128797","article-title":"Comparison of three zinc binding groups for HDAC inhibitors \u2013 a potency, selectivity and enzymatic kinetics study","volume":"70","author":"Yue","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13148-018-0531-y","article-title":"Effects of novel HDAC inhibitors on urothelial carcinoma cells","volume":"10","author":"Kaletsch","year":"2018","journal-title":"Clin. Epigenet."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6890-14-10","article-title":"Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer","volume":"14","author":"Poyet","year":"2014","journal-title":"BMC Clin. Pathol."},{"issue":"48","key":"10.1016\/j.ejmech.2026.118806_bib36","doi-asserted-by":"crossref","first-page":"33394","DOI":"10.1074\/jbc.M804788200","article-title":"Down-regulation of Micro-RNA-1 (MiR-1) in lung cancer: suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by MiR-1","volume":"283","author":"Nasser","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118806_bib37","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1091\/mbc.e08-02-0139","article-title":"HDAC4 promotes growth of Colon cancer cells via repression of P21","volume":"19","author":"Wilson","year":"2008","journal-title":"Mol. Biol. Cell"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118806_bib38","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1158\/0008-5472.CAN-06-4152","article-title":"Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays","volume":"67","author":"Stark","year":"2007","journal-title":"Cancer Res."},{"issue":"5797","key":"10.1016\/j.ejmech.2026.118806_bib39","first-page":"268","article-title":"The consensus coding sequences of human breast and colorectal cancers","volume":"314","author":"Sjoblom","year":"2006","journal-title":"Science (1979)"},{"issue":"23","key":"10.1016\/j.ejmech.2026.118806_bib40","doi-asserted-by":"crossref","first-page":"11298","DOI":"10.1158\/0008-5472.CAN-06-0049","article-title":"Histone deacetylase (HDAC) inhibitor LBH589 increases duration of \u03b3-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non\u2013small cell lung cancer","volume":"66","author":"Geng","year":"2006","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118806_bib41","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1083\/jcb.200209065","article-title":"Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response","volume":"160","author":"Kao","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118806_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118108","article-title":"Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in vitro and in vivo","volume":"187","author":"Shen","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2015.09.018","article-title":"Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3\u03b2 to suppress MTOR and \u03b2-Catenin signaling pathways","volume":"370","author":"Hsieh","year":"2016","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118806_bib44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1535-7163.MCT-15-0618","article-title":"Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms","volume":"15","author":"Pinkerneil","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118806_bib45","doi-asserted-by":"crossref","DOI":"10.3892\/or.2011.1553","article-title":"HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin","author":"Chen","year":"2011","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118806_bib46","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/ijms20061291","article-title":"Revisiting histone deacetylases in human tumorigenesis: the paradigm of urothelial bladder cancer","volume":"20","author":"Giannopoulou","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118806_bib47","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4161\/cbt.28469","article-title":"Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells","volume":"15","author":"Rosik","year":"2014","journal-title":"Cancer Biol. Ther."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118806_bib48","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41416-023-02195-0","article-title":"Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling","volume":"128","author":"Tsai","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3892\/ol.2020.12315","article-title":"Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment","volume":"21","author":"Kuroki","year":"2020","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118806_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123191","article-title":"APKC phosphorylation of HDAC6 results in increased deacetylation activity","volume":"10","author":"Du","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118806_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3892\/ijmm.2025.5578","article-title":"Histone deacetylase 6: a new player in oxidative stress-associated disorders and cancers","volume":"56","author":"Qu","year":"2025","journal-title":"Int. J. Mol. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118806_bib52","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.3390\/ijms24054720","article-title":"Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based inhibitors of histone deacetylase 6 in vitro and in cells","volume":"24","author":"Ptacek","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94923-w","article-title":"A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for alzheimer's disease and tauopathy in mice","volume":"11","author":"Onishi","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118806_bib54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2013.05.020","article-title":"Class I HDACs share a common mechanism of regulation by inositol phosphates","volume":"51","author":"Millard","year":"2013","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118806_bib55","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/ph16030356","article-title":"Photocaged histone deacetylase inhibitors as prodrugs in targeted cancer therapy","volume":"16","author":"Kraft","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"79","key":"10.1016\/j.ejmech.2026.118806_bib56","doi-asserted-by":"crossref","first-page":"11087","DOI":"10.1039\/D2CC03712B","article-title":"Development of the first non-hydroxamate selective HDAC6 degraders","volume":"58","author":"Keuler","year":"2022","journal-title":"Chem. Commun."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118806_bib57","doi-asserted-by":"crossref","first-page":"15457","DOI":"10.1021\/acs.jmedchem.2c01418","article-title":"Development of fluorinated peptoid-based histone deacetylase (HDAC) inhibitors for therapy-resistant acute leukemia","volume":"65","author":"Re\u00dfing","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118806_bib58","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1021\/acs.jmedchem.5c00939","article-title":"Discovery of histone deacetylase 8-Specific proteolysis-targeting chimeras with anticancer activity against hematological malignancies","volume":"69","author":"Zhai","year":"2026","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118806_bib59","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1021\/acsptsci.5c00562","article-title":"Ortho -Hydroxyanilides: slow-acting, selective histone deacetylase 1\/2 inhibitors suitable for photocaging applications","volume":"8","author":"Honin","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:44:35Z","timestamp":1781271875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":59,"alternative-id":["S0223523426002515"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118806","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fine-tuning the combination of novel spirocyclic capping moieties and heterocyclic zinc binding groups for selective HDAC6 inhibition: design, synthesis, kinetic and biological studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118806"}}